Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population
- PMID: 34751487
- DOI: 10.1111/hepr.13728
Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population
Abstract
Aim: The global burden of chronic liver disease is substantial. Limited studies have reported the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and liver fibrosis among middle-aged and older people. Therefore, we aimed to determine the nationwide prevalence of and associated factors for MAFLD and fibrosis in adults aged 45-79 years from the United States.
Methods: This cross-sectional study utilized data from the 2017-2018 cycle of the National Health and Nutrition Examination Survey conducted with a nationally representative sample of the civilian, noninstitutionalized US population. Hepatic steatosis and fibrosis were assessed by transient elastography with controlled attenuation parameter and liver stiffness measurement, respectively.
Results: A total of 1186 eligible participants aged 45-79 years were finally included in the analyses. The estimated prevalence of MAFLD, significant fibrosis (F ≥ F2), and advanced fibrosis (F ≥ F3) was 48.6% (95% confidence interval [CI], 43.1%-54.0%), 9.5% (95% CI, 6.8%-12.7%), and 6.7% (95% CI, 4.1%-10.1%), respectively. Multivariable logistic regression revealed an increased MAFLD predisposition in subjects with metabolic disorders including overweight/obesity, abdominal obesity, hypertension, and diabetes mellitus. Moreover, the presence of depression was an independent and strong predictor of MAFLD risk (odds ratio = 3.23; 95% CI, 1.37-7.11). Elevated liver enzymes, hypertension, diabetes mellitus, hepatitis virus infection, and steatosis were associated with a high risk of significant fibrosis.
Conclusions: Newly defined MAFLD is highly prevalent in the US middle-aged and older population. Approximately 1 in 10 people has significant liver fibrosis. In addition to metabolic disorders, the presence of depression potentially increases the risk of MAFLD.
Keywords: associated factors; depression; liver fibrosis; metabolic dysfunction-associated fatty liver disease; older people; prevalence.
© 2021 The Japan Society of Hepatology.
Similar articles
-
Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents.Hepatol Commun. 2022 Aug;6(8):2070-2078. doi: 10.1002/hep4.1969. Epub 2022 Apr 26. Hepatol Commun. 2022. PMID: 35470984 Free PMC article.
-
Associations of depression score with metabolic dysfunction-associated fatty liver disease and liver fibrosis.J Affect Disord. 2023 Aug 1;334:332-336. doi: 10.1016/j.jad.2023.04.093. Epub 2023 May 3. J Affect Disord. 2023. PMID: 37142003
-
Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis.J Affect Disord. 2023 May 15;329:184-191. doi: 10.1016/j.jad.2023.02.101. Epub 2023 Feb 23. J Affect Disord. 2023. PMID: 36841305
-
FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic.Life (Basel). 2021 Feb 14;11(2):143. doi: 10.3390/life11020143. Life (Basel). 2021. PMID: 33672864 Free PMC article. Review.
-
MAFLD: what 2 years of the redefinition of fatty liver disease has taught us.Ther Adv Endocrinol Metab. 2022 Nov 22;13:20420188221139101. doi: 10.1177/20420188221139101. eCollection 2022. Ther Adv Endocrinol Metab. 2022. PMID: 36439029 Free PMC article. Review.
Cited by
-
Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Cognitive Impairment and All-Cause Dementia: A Comprehensive Review.Turk J Gastroenterol. 2024 Feb;35(2):76-82. doi: 10.5152/tjg.2024.23629. Turk J Gastroenterol. 2024. PMID: 38454238 Free PMC article. Review.
-
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC Med. 2024 Mar 6;22(1):101. doi: 10.1186/s12916-024-03315-0. BMC Med. 2024. PMID: 38448943 Free PMC article.
-
Significant fibrosis assessed by liver biopsy among Chinese bariatric surgery patients: A prospective cross-sectional study.Front Endocrinol (Lausanne). 2023 Jan 30;14:1090598. doi: 10.3389/fendo.2023.1090598. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36793287 Free PMC article.
-
Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults.Front Endocrinol (Lausanne). 2022 Sep 16;13:1004855. doi: 10.3389/fendo.2022.1004855. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36187093 Free PMC article.
References
REFERENCES
-
- Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-90.
-
- Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263-73.
-
- Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-31.
-
- Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-55.
-
- Haugen CE, Holscher CM, Garonzik-Wang J, Pozo M, Warsame F, McAdams-DeMarco M, et al. National trends in liver transplantation in older adults. J Am Geriatr Soc. 2018;66:2321-6.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
